ClinicalTrials.gg
Active, not recruitingNCT06361433RAINBOW-HxUpdated Oct 15, 2026

Intracerebral Transplantation of Autologous MSC Combined With Scaffold Product for Chronic Intracerebral Hemorrhage

A Phase 1/2 interventional study of HUFF-01 in Intracerebral Hemorrhage, sponsored by Hokkaido University Hospital. Active, not recruiting at 1 site in Japan. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Hokkaido University Hospital · Phase 1/2, Interventional, and Treatment

How we know

Updated Oct 15, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
20 Years to 70 Years
Sex
All
01

Study summary

The goal of this clinical trial is to test intracerebral transplantation of stem cell product in patient with chronic intracerebral hemorrhage. The main questions aims to answer are:

  • The safety of the product
  • The efficacy of the product
Read the detailed description

Introduction:

Intracerebral hemorrhage stands as a leading global cause of death and disability, posing a significant challenge with limited treatment options, especially for chronic patients. Recent advances of stem cell therapies have opened new avenues for therapeutic potential. The investigators' previous preclinical research has demonstrated that intracerebral transplantation of bone marrow stromal cells (BMSCs) combined with a recombinant human collagen type I scaffold enables higher cell survival and engraftment, holds promising potential. The investigators present the protocol for a novel clinical trial, named "Research on Advanced Intervention using Novel Bone Marrow Stem Cells for Chronic Intracerebral Hemorrhage" (RAINBOW-Hx).

Methods and Analysis:

RAINBOW-Hx is a phase I/II, open-label, uncontrolled study with the primary objective of assessing the safety and efficacy of intracerebral transplantation of autologous BMSCs combined with the scaffold (HUFF-01) in patients with chronic intracerebral hemorrhage. Eight patients, experiencing moderate to severe neurological deficits for 12 months or longer, will be enrolled. The hemorrhage location will be limited to the basal ganglia and thalamus. Approximately 50 mL of bone marrow will be extracted from the iliac bone of each patient, and BMSCs will be cultured using autologous platelet lysate. Three days before transplantation, BMSCs will be combined with the scaffold to generate HUFF-01. Each patient will receive a 50,000 HUFF-01 dose, containing approximately 50 million BMSCs, through stereotactic transplantation into the hemorrhagic cavity. Neurological assessments, magnetic resonance imaging, 18F-fluorodeoxyglucose positron emission tomography, and 123I-Iomazenil single-photon emission computed tomography will be performed for one year after administration.

02

Conditions studied

  • Intracerebral Hemorrhage

Keywords

  • Mesenchymal stromal cell
  • scaffold
  • chronic
  • intracerebral hemorrhage
  • intraparenchymal transplantation
03

In context

Cerebral Hemorrhage

458 studies on the registry are indexed under Cerebral Hemorrhage; 173 are open to participants now.

This study's planned enrollment of 8 is below the median of 100 across 269 interventional studies indexed under Cerebral Hemorrhage.

Browse Cerebral Hemorrhage studies →

Lead sponsor

Hokkaido University Hospital is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Age between 20 and 70 years
  • 2. Clinical diagnosis of intracerebral hemorrhage 12 month or more from onset
  • 3. Hemorrhagic location of unilateral basal ganglia or thalamus
  • 4. Moderate to severe neurological symptoms; mRS 3 or 4, and Brunnstrom stage Ⅲ or IV
  • 5. No significant neurological impairment before hemorrhage (Pre-hemorrhagic mRS of 0 or 1)
  • 6. Subjects who can give by its self

Exclusion criteria

Exclusion Criteria:

  • 1. Severe microbleeds found by T2*
  • 2. Hemorrhagic cavity less than 2 mL
  • 3. The hemorrhage is due to arteriovenous malformation, cerebral aneurysm, and Moyamoya disease
  • 4. Subject showing obvious communication between the hemorrhagic cavity and lateral ventricle on MRI
  • 5. Subject showing severe lower extremity contracture (Maximum knee extension less than -15 degrees, Maximum ankle flexion less than 0 degree)
  • 6. Subject's body weight less than 45 kg for male and 40kg for female
  • 7. Anaemia (Hg \< 10·0 g/dL)
  • 8. Thrombocytopaenia ( count \< 100,000/mm3)
  • 9. Severe heart disease (ischaemic heart disease, heart failure)
  • 10. Uncontrolled hypertension, despite antihypertensive therapy
  • 11. Carriers of infectious disease: syphilis, , , -1/HIV-2, HTLV-1, parvovirus B19
  • 12. Pregnant or lactating or expecting to become pregnant during the study
  • 13. History of
  • 14. Systemic organ failure ≤ 3·0× Total ≤ 1·5× upper limit of normal Serum creatinine ≤ 1·5× upper limit of normal
  • 15. Known serious allergy to any agents used in the study
  • 16. for magnetic resonance imaging
  • 17. Any condition that in the judgement of the investigator would place the patient at undue risk
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (estimated)

Study arms

  • Experimental
    Cell product transplantation

    Autologous MSC with scaffold containing approximately 5 x 10\^7 MSC cells.

    Drug: HUFF-01

Interventions

  • DrugHUFF-01

    autologous MSC combined with scaffold

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

    Listing unexpected CTCAE grade changes in physiological (physical examination/blood test) and Radiographical (MRI/CT) examination

    Time frame: one year

Secondary outcomes

  1. Change in mRS examination

    Percentage of the patients number who showed improvement of mRS (0-6, higher score means worse outcome) of more than 1 point

    Time frame: One year

  2. Change in NIHSS examination

    Mean improvement of NIHSS (0-42, higher score means worse outcome)

    Time frame: One year

  3. Change in FIM examination

    Mean improvement of FIM (18-126, higher score means better outcome)

    Time frame: One year

  4. Change in Fugl-Myer examination

    Mean improvement of Fugl-Myer (0-226, higher score means better outcome)

    Time frame: One year

  5. Change in Barthal index examination

    Mean improvement of Barthal index (0-100, higher score means better outcome)

    Time frame: One year

  6. Change in FDG-PET examination

    Mean improvement of FDG-PET set for ipsilateral motor cortex

    Time frame: One year

  7. Change in IMZ-SPECT examination

    Mean improvement of IMZ-SPECT set for ipsilateral motor cortex

    Time frame: One year

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Dec 2023 (actual). Primary completion is estimated for Sep 2027, 45 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Feb 2026 → Sep 2027 and completion Feb 2026 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2024
First posted
Apr 11, 2024
StartActual
Dec 1, 2023
Primary completionEst.
Sep 2027was Feb 2026
CompletionEst.
Sep 2027was Feb 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 15, 2026
Primary completion
Feb 2026→Sep 2027
Oct 15, 2026
Study completion
Feb 2026→Sep 2027
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Recruiting→Active, not recruiting
    Primary completion Feb 2026→Sep 2027
    Study completion Feb 2026→Sep 2027
    + 5 other changes: index terms, verification date, criteria formatting, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06361433
Lead sponsor
Hokkaido University Hospital
Collaborators
Japan Agency for Medical Research and Development
Responsible party
Masahito Kawabori (Lecturer, Hokkaido University Hospital) — Principal investigator
First posted
Apr 11, 2024
Start date
Dec 1, 2023
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Oct 15, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion